nach oben

Erschienen in:

22.07.2020 | Original Article

Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report

verfasst von: Mustafa Zafer Temiz, Aykut Colakerol, Ismail Ulus, Enes Kilic, Filip Paslanmaz, Sergen Sahin, Emrah Yuruk, Engin Kandirali, Atilla Semercioz, Ahmet Yaser Muslumanoglu

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine whether there is an association between blood eosinophil count and percentage with the recurrence of nonmuscle invasive bladder cancer (NMIBC) during Bacillus Calmette-Guérin (BCG) maintenance therapy with our preliminary results.

Methods

A total of 53 patients with NMIBC underwent BCG immunotherapy between January 2015 and September 2018, and met our inclusion criteria were included in the study. The parameters age, gender, smoking status, comorbidity, blood neutrophil, lymphocyte and eosinophil counts, blood eosinophil percentage, previous single postoperative intravesical chemotherapy instillation, tumor characteristic, and total and maintenance dose numbers of BCG were extracted from our medical records and compared between patients with response and with recurrence.

Results

Blood eosinophil count and percentage were significantly higher in patients with recurrence compared to patients with response (0.263 ± 0.37 vs. 0.0134 ± 0.021, p = 0.01 and 0.31 ± 0.29 vs. 0.17 ± 0.27, p = 0.01). Other parameters were similar in patients with recurrence and response. Receiver-operating characteristic analysis showed a considerable diagnostic value of blood eosinophil count and percentage in the prediction of bladder cancer recurrence during BCG immunotherapy.

Conclusion

Blood eosinophil count and percentage in patients with NMIBC can predict the disease recurrence during the BCG immunotherapy. Our research raised new questions and assumptions about the role of eosinophils during BCG immunotherapy.

Kang M, Jeong CW, Kwak C, Kim HH, Ku JH (2017) Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget 8:12891–12901. https://doi.org/10.18632/oncotarget.14179CrossRefPubMed

Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y (2017) Bladder cancer. Nat Rev Dis Primers 3:17022. https://doi.org/10.1038/nrdp.2017.22CrossRef

Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus calmette-guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69:1046–1052. https://doi.org/10.1016/j.eururo.2016.01.006CrossRefPubMed

Nunez-Nateras R, Castle EP, Protheroe CA et al (2014) Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 32(45):e23–30. https://doi.org/10.1016/j.urolonc.2013.06.008CrossRef

Zlotta AR, Fleshner NE, Jewett MA (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3:S199–205CrossRef

Kamat AM, Li R, O'Donnell MA et al (2018) Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review. Eur Urol 73:738–748. https://doi.org/10.1016/j.eururo.2017.10.003CrossRefPubMed

Prakash Babu S, Narasimhan PB, Babu S (2019) Eosinophil polymorphonuclear leukocytes in TB: what we know so far. Front Immunol 10:2639. https://doi.org/10.3389/fimmu.2019.02639CrossRefPubMedPubMedCentral

Kirman J, Zakaria Z, McCoy K, Delahunt B, Le Gros G (2000) Role of eosinophils in the pathogenesis of Mycobacterium bovis BCG infection in gamma interferon receptor-deficient mice. Infect Immun 68:2976–2978. https://doi.org/10.1128/iai.68.5.2976-2978.2000CrossRefPubMedPubMedCentral

Castro AG, Esaguy N, Macedo PM, Aguas AP, Silva MT (1991) Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils in vivo and are ingested by the attracted granulocytes. Infect Immun 59:3009–3014CrossRef

10.

Montironi R, Lopez-Beltran A (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13:143–153. https://doi.org/10.1177/106689690501300203CrossRefPubMed

11.

Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB (2018) Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol 73:560–569. https://doi.org/10.1016/j.eururo.2017.12.018CrossRef

12.

Johnston LK, Bryce PJ (2017) Understanding interleukin 33 and its roles in eosinophil development. Front Med 4:51. https://doi.org/10.3389/fmed.2017.00051CrossRef

13.

Rosenberg HF, Dyer KD, Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13:9–22. https://doi.org/10.1038/nri3341CrossRef

14.

Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G (2018) Eosinophils: the unsung heroes in cancer? Oncoimmunology 7:e1393134. https://doi.org/10.1080/2162402X.2017.1393134CrossRefPubMed

15.

Bochner BS (2015) Novel therapies for eosinophilic disorders. Immunol Allergy Clin N Am 35:577–598. https://doi.org/10.1016/j.iac.2015.05.007CrossRef

16.

Lucarini V, Ziccheddu G, Macchia I et al (2017) IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology 6:e1317420. https://doi.org/10.1080/2162402X.2017.1317420CrossRefPubMedPubMedCentral

17.

Horiuchi T, Weller PF (1997) Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 17:70–77. https://doi.org/10.1165/ajrcmb.17.1.2796CrossRefPubMed

18.

Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934CrossRef

19.

Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, de Fine ON, Bjerrum OW (2014) Eosinophilia in routine blood samples as a biomarker for solid tumor development - a study based on the Copenhagen Primary Care Differential Count (CopDiff) Database. Acta Oncol 53:1245–1250. https://doi.org/10.3109/0284186X.2014.887857CrossRefPubMed

20.

Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Diez G, de Medina S, Abbou CC, Chopin DK (2001) Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guerin treatment. BJU Int 88:602–610CrossRef

21.

Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M (2017) Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother CII 66:427–440. https://doi.org/10.1007/s00262-016-1945-zCrossRefPubMed

22.

Miyata Y, Sakai H (2015) Predictive markers for the recurrence of nonmuscle invasive bladder cancer treated with intravesical therapy. Dis Mark 2015:857416. https://doi.org/10.1155/2015/857416CrossRef

23.

Diny NL, Rose NR, Cihakova D (2017) Eosinophils in autoimmune diseases. Front Immunol 8:484. https://doi.org/10.3389/fimmu.2017.00484CrossRefPubMedPubMedCentral

24.

Caldwell JM, Collins MH, Stucke EM, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Rothenberg ME (2014) Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol 134:1114–1124. https://doi.org/10.1016/j.jaci.2014.07.026CrossRefPubMedPubMedCentral

25.

Lowe D, Fletcher CD, Gower RL (1984) Tumour-associated eosinophilia in the bladder. J Clin Pathol 37:500–502CrossRef

26.

Driss V, Legrand F, Hermann E et al (2009) TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood 113:3235–3244. https://doi.org/10.1182/blood-2008-07-166595CrossRefPubMed

27.

Borelli V, Vita F, Shankar S, Soranzo MR, Banfi E, Scialino G, Brochetta C, Zabucchi G (2003) Human eosinophil peroxidase induces surface alteration, killing, and lysis of Mycobacterium tuberculosis. Infect Immun 71:605–613CrossRef

28.

Siracusano S, Vita F, Abbate R, Ciciliato S, Borelli V, Bernabei M, Zabucchi G (2007) The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 51:1589–1597. https://doi.org/10.1016/j.eururo.2006.11.045 (discussion 97–99)CrossRefPubMed

29.

Durrington HJ, Gioan-Tavernier GO, Maidstone RJ et al (2018) Time of day affects eosinophil biomarkers in asthma: implications for diagnosis and treatment. Am J Respir Crit Care Med 198:1578–1581. https://doi.org/10.1164/rccm.201807-1289LECrossRefPubMedPubMedCentral

30.

Sennels HP, Jorgensen HL, Hansen AL, Goetze JP, Fahrenkrug J (2011) Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Investig 71:532–541. https://doi.org/10.3109/00365513.2011.602422CrossRef

31.

Wu HX, Zhuo KQ, Cheng DY (2019) Peripheral blood eosinophil as a biomarker in outcomes of acute exacerbation of chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis 14:3003–3015. https://doi.org/10.2147/COPD.S226783CrossRef

32.

Pavord ID, Agusti A (2016) Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. Eur Respir J 47:1299–1303. https://doi.org/10.1183/13993003.00055-2016CrossRefPubMed

33.

Bafadhel M, Pavord ID, Russell REK (2017) Eosinophils in COPD: just another biomarker? Lancet Respir Med 5:747–759. https://doi.org/10.1016/S2213-2600(17)30217-5CrossRefPubMed

34.

Onesti CE, Josse C, Poncin A, Freres P, Poulet C, Bours V, Jerusalem G (2018) Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget 9:33719–33733. https://doi.org/10.18632/oncotarget.26120CrossRefPubMedPubMedCentral

35.

Moreira A, Leisgang W, Schuler G, Heinzerling L (2017) Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy 9:115–121. https://doi.org/10.2217/imt-2016-0138CrossRefPubMed

36.

Sylman JL, Mitrugno A, Atallah M et al (2018) The predictive value of inflammation-related peripheral blood measurements in cancer staging and prognosis. Front Oncol 8:78. https://doi.org/10.3389/fonc.2018.00078CrossRefPubMedPubMedCentral

Titel: Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report
verfasst von: Mustafa Zafer Temiz
Aykut Colakerol
Ismail Ulus
Enes Kilic
Filip Paslanmaz
Sergen Sahin
Emrah Yuruk
Engin Kandirali
Atilla Semercioz
Ahmet Yaser Muslumanoglu
Publikationsdatum: 22.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 1/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02673-x

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report